Kazia Therapeutics Limited (KZIA) AI Stock Analysis
KZIA AI stock analysis summary
AI ResearchKazia Therapeutics Limited (KZIA) is a clinical-stage oncology biotechnology company focused on brain cancer and other solid tumors. The company generated $1.9M in trailing twelve-month revenue, holds $69.4M in cash and short-term investments, and carries an enterprise value of $97.8M. Operating profitability remains deeply negative, with a trailing twelve-month operating margin of -14641.0%.
- Market cap
- $82.8M
- Revenue (TTM)
- $1.9M
- P/E
- — fwd 12.8x
- 1Y return
- 3.7% S&P 500 16.8%
- Avg. target
- $28.21 289.2% vs last close
Bull case
- The company holds net cash of $69.3M with minimal debt of $98,708 as of December 31, 2025.
- Wall Street analysts maintain 6 positive ratings (4 Strong Buy and 2 Buy) with a mean price target of $28.21.
- Quarterly revenue grew 312.4% year over year for the period ended December 31, 2025.
Bear case
- Revenue has contracted at a five-year CAGR of -46.8% from FY2020 through FY2025, with FY2025 revenue at just $42,000.
- Cash burn remains persistent, evidenced by FY2025 free cash flow of -$13.3M and a trailing EPS of -$6.85.
- Shareholder dilution has been substantial, with the share count expanding 1352.7% over the past 5 fiscal years.
What Kazia Therapeutics does
Kazia Therapeutics Limited is a biotechnology company dedicated to developing innovative anti-cancer therapies to address significant unmet medical needs. Its core pipeline asset is Paxalisib, a brain-penetrant inhibitor of the PI3K/Akt/mTor pathway designed as a potential treatment for glioblastoma, an aggressive form of brain cancer. The company is also advancing EVT801, an investigational drug aimed at treating various other cancers. Founded in 1994 as Novogen Limited and rebranded in November 2017, Kazia Therapeutics is based in Sydney, Australia, and operates with 6 employees.
Growth and profitability
Annual revenue has fluctuated significantly over recent fiscal periods. Top-line revenue dropped from $15.2M in FY2021 to $10,000 in FY2022 and $555 in FY2023, before rebounding to $2.3M in FY2024 and falling 98.2% to $42,000 in FY2025. Over the five-year span from FY2020 to FY2025, revenue posted a compound annual growth rate of -46.8%. Net losses were -$20.5M in FY2023, -$26.8M in FY2024, and -$20.7M in FY2025, reflecting continued research and development spending, which stood at $7.3M in FY2025. In the trailing twelve months through the quarter ended December 31, 2025, revenue totaled $1.9M, while quarterly revenue grew 312.4% year over year.
Balance sheet and cash flow
As of December 31, 2025, Kazia Therapeutics reported $69.4M in cash and short-term investments against total debt of $98,708, yielding a net cash balance of $69.3M. The company maintains a current ratio of 2.87 and a debt-to-equity ratio of 0.00 on shareholders' equity of $46.4M. Cash burn continues, with operating cash flow and free cash flow both at -$13.3M in FY2025. Over the last five fiscal years, the share count increased by 1352.7%, reflecting financing through equity dilution rather than debt issuance.
Valuation and performance
KZIA trades at a forward P/E of 12.8x, compared to 17.3x for the median of its US-listed Healthcare peers. Its price-to-sales multiple is 43.6x, compared to the peer median of 4.1x, and its price-to-book ratio is 4.4x. The company's PEG ratio stands at 1.01. Over the past year, Kazia Therapeutics shares rose 3.7%, lagging the 16.8% return for the S&P 500 (SPY). Over a five-year period, the stock fell 98.6%, while SPY returned 83.0%. The stock trades 30.7% below its 200-day moving average.
What analysts expect
Consensus coverage includes 4 Strong Buy ratings and 2 Buy ratings, with zero Hold or Sell recommendations. The mean price target is $28.21, representing a 289.2% premium over the last close of $7.25. For the current fiscal year ending June 30, 2026, analysts estimate an EPS of -$0.02 and revenue of $676,980. For the next fiscal year, projected EPS is -$0.02 on revenue of $642,000. The company beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is November 6, 2026.
Key risks and what to watch
- The five-year share price return of -98.6% highlights long-term equity depreciation.
- High volatility is indicated by a beta of 2.27 and shares trading 30.7% below their 200-day moving average.
- Operational losses are significant, with a trailing twelve-month operating margin of -14641.0% and return on equity of -106.9%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this KZIA AI stock analysis
This page is an AI-written research summary of Kazia Therapeutics Limited (KZIA). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: KZIA income statement, KZIA balance sheet, KZIA key metrics, KZIA analyst forecast, KZIA chart. See the KZIA stock overview for the latest quote and news.
KZIA AI stock analysis FAQ
What is Kazia Therapeutics' primary drug candidate?
The company's lead drug candidate is Paxalisib, a brain-penetrant inhibitor targeting the PI3K/Akt/mTor pathway for the potential treatment of glioblastoma. It is also developing EVT801 for various other cancers.
Does Kazia Therapeutics pay a dividend?
No, Kazia Therapeutics does not pay a dividend. The company directs its capital toward research and clinical development.
How strong is Kazia Therapeutics' balance sheet?
As of December 31, 2025, the company had $69.4M in cash and short-term investments and only $98,708 in total debt, giving it a current ratio of 2.87.
What do analysts forecast for KZIA stock?
Analysts hold 4 Strong Buy and 2 Buy ratings with a mean price target of $28.21, which sits 289.2% above the last closing price of $7.25. The consensus estimate projects an EPS of -$0.02 on $676,980 in revenue for FY2026.